- Gramicidin A
-
- $113.00 / 1mg
-
2026-01-05
- CAS:11029-61-1
- Min. Order:
- Purity:
- Supply Ability: 10g
- GRAMICIDIN A USP/EP/BP
-
- $1.10 / 1g
-
2025-11-18
- CAS:11029-61-1
- Min. Order: 1g
- Purity: 99.9%
- Supply Ability: 100 Tons Min
|
| | GRAMICIDIN A Basic information |
| | GRAMICIDIN A Chemical Properties |
| storage temp. | 2-8°C | | solubility | ethanol: soluble | | form | White to off-white solid | | color | colorless or white | | BRN | 6461131 | | Sequence | {For}-Val-Gly-Ala-{D-Leu}-Ala-{D-Val}-Val-{D-Val}-Trp-{D-Leu}-Trp-{D-Leu}-Trp-{D-Leu}-Trp-{NHCH2CH2OH} | | InChIKey | ZWCXYZRRTRDGQE-LUPIJMBPSA-N |
| Hazard Codes | Xn | | Risk Statements | 22 | | WGK Germany | 3 | | RTECS | MD8230000 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral | | Toxicity | mouse,LD50,intraperitoneal,60mg/kg (60mg/kg),"CRC Handbook of Antibiotic Compounds," Vols.1- , Berdy, J., Boca Raton, FL, CRC Press, 1980Vol. 4(1), Pg. 240, 1980. |
| | GRAMICIDIN A Usage And Synthesis |
| Uses | Gramicidin A is an effective antibiotic against Gram positive organisms. | | Biological Activity | Cell permeable: no', 'Primary Target
Causes the formation of a monovalent cation-selective ion channel', 'Product does not compete with ATP.', 'Reversible: no | | in vivo | Gramicidin A (0.11 mg/kg; intratumoral injection; twice weekly for 14 days) inhibits the growth of RCC tumor xenografts[2].
Gramicidin A (0.22 mg/kg; intratumoral injection; thrice weekly for 26 days) inhibits the growth and angiogenesis of VHL-expressing RCC tumor xenografts[3]. | Animal Model: | Female hairless Nu/J mice, 6- to 8-week old, injected subcutaneously with a suspension of SN12C cells (1.0 × 106) in a 50% growth factor–reduced Matrigel solution[2] | | Dosage: | 0.11 mg/kg body weight | | Administration: | Intratumoral injection, twice weekly for 14 days | | Result: | The average tumor mass was reduced by approximately 40% without significant toxicity. |
| Animal Model: | Female hairless 6- to 8-week-old Nu/J mice, injected subcutaneously with a suspension of Caki-1-td-Tomato cells (1.5 × 106) in a 50% growth factor-reduced Matrigel solution[3]. | | Dosage: | 0.22 mg/kg | | Administration: | Intratumoral injection, thrice weekly for 26 days | | Result: | Inhibited tumor growth. HIF-2α and GAPDH protein expression was substantially reduced. |
| | Purification Methods | Purify gramicidin A by countercurrent distribution from *C6H6/CHCl3, MeOH/H2O (15:15:23:7) with 5000 tubes. Fractions are examined by UV (280nm) of small aliquots. Separation from gramicidin C and other material occurred after 999 transfers. [Gross & Witkop Biochemistry 4 2495 1965, Bauer et al. Biochemistry 11 3266 1972.] Purify it finally by recrystallisation from EtOH/H2O and dry it at 100o/10-2mm over KOH. It forms platelets m 229-230o. It is almost insoluble in H2O (0.6%) but soluble in lower alcohols, dry Me2CO, dioxane, acetic acid and pyridine. The commercial material is more difficult to crystallise than the synthetic compound. [Sarges & Witkop J Am Chem Soc 86 1861 1964, 87 2011, 2020 1965.] It has characteristic [] D20 +27.3o (c 1.3, MeOH) and UV max at 282nm ( 22,100). The N-carbamoyldeformyl gramicidine A precipitates from EtOAc/pet ether (b 40-60o). [Beilstein 26 III/IV 4273.] |
| | GRAMICIDIN A Preparation Products And Raw materials |
|